JPH04202194A - Production of oxazopyrroloquinoline - Google Patents
Production of oxazopyrroloquinolineInfo
- Publication number
- JPH04202194A JPH04202194A JP33036090A JP33036090A JPH04202194A JP H04202194 A JPH04202194 A JP H04202194A JP 33036090 A JP33036090 A JP 33036090A JP 33036090 A JP33036090 A JP 33036090A JP H04202194 A JPH04202194 A JP H04202194A
- Authority
- JP
- Japan
- Prior art keywords
- pqq
- solution
- ammonia
- methanol
- formaldehyde
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000004519 manufacturing process Methods 0.000 title claims description 7
- MMXZSJMASHPLLR-UHFFFAOYSA-N pyrroloquinoline quinone Chemical compound C12=C(C(O)=O)C=C(C(O)=O)N=C2C(=O)C(=O)C2=C1NC(C(=O)O)=C2 MMXZSJMASHPLLR-UHFFFAOYSA-N 0.000 claims abstract description 79
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims abstract description 47
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims abstract description 27
- 229910021529 ammonia Inorganic materials 0.000 claims abstract description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 abstract description 30
- 238000006243 chemical reaction Methods 0.000 abstract description 17
- 230000000694 effects Effects 0.000 abstract description 7
- 241000894006 Bacteria Species 0.000 abstract description 5
- 206010029155 Nephropathy toxic Diseases 0.000 abstract description 4
- 230000007694 nephrotoxicity Effects 0.000 abstract description 4
- 231100000417 nephrotoxicity Toxicity 0.000 abstract description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract description 3
- 229910052799 carbon Inorganic materials 0.000 abstract description 3
- 150000001875 compounds Chemical class 0.000 abstract description 3
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 abstract description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 abstract description 2
- 235000011130 ammonium sulphate Nutrition 0.000 abstract description 2
- 230000003266 anti-allergic effect Effects 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 42
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 7
- 235000011114 ammonium hydroxide Nutrition 0.000 description 7
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 235000011121 sodium hydroxide Nutrition 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241000862974 Hyphomicrobium Species 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000005273 aeration Methods 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000005515 coenzyme Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 2
- 229910000368 zinc sulfate Inorganic materials 0.000 description 2
- 239000011686 zinc sulphate Substances 0.000 description 2
- 235000009529 zinc sulphate Nutrition 0.000 description 2
- 229930189936 Glyoxalase Natural products 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 108010048916 alcohol dehydrogenase (acceptor) Proteins 0.000 description 1
- 230000001437 anti-cataract Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000003518 caustics Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000002554 disease preventive effect Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 229910000357 manganese(II) sulfate Inorganic materials 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 239000010413 mother solution Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
【発明の詳細な説明】
[産業上の利用分野]
本発明は、オキサゾピロロキノリンの製造方法に関し、
さらに詳細には、ピロロキノリンキノンからオキサゾピ
ロロキノリンの製造法に係わる。[Detailed Description of the Invention] [Industrial Application Field] The present invention relates to a method for producing oxazopyrroquinoline,
More specifically, the present invention relates to a method for producing oxazopyrroquinoline from pyrroloquinoline quinone.
オキサゾピロロキノリン(以下OPQと略す)は、別名
2,8,104リカルボキシーIH−オキサゾ[5,4
−h]−ピロロ[2,3−f]キノリンであり、化学構
造式は、以下のごとくである。Oxazopyrroloquinoline (hereinafter abbreviated as OPQ) is also known as 2,8,104-licarboxy IH-oxazo[5,4
-h]-pyrrolo[2,3-f]quinoline, and its chemical structural formula is as follows.
○PQは、ピロロキノリンキノン(以下 PQQと記す
)の誘導体であり、今後、医薬品として、開発しうる重
要な物質である。なお、PQQは、1979年にメタノ
ール資化性細菌のメタノール脱水素酵素の補酵素として
見い出された。○PQ is a derivative of pyrroloquinoline quinone (hereinafter referred to as PQQ), and is an important substance that can be developed as a pharmaceutical in the future. PQQ was discovered in 1979 as a coenzyme of methanol dehydrogenase of methanol-assimilating bacteria.
[従来技術、発明が解決しようとする問題点]PQQは
、細菌に限らず、真核生物のカビ、酵母、さらには、姉
乳動物にも存在し、補酵素として重要な働きをになって
いる。また、さらに、近年までに細胞の増殖促進作用(
特開昭61−58584号公報、同63−233783
号公報)、抗白内障作用(特開昭63−41421号公
報。[Prior art and problems to be solved by the invention] PQQ is present not only in bacteria but also in eukaryotic molds, yeast, and even sister mammals, and plays an important role as a coenzyme. There is. In addition, in recent years, cell proliferation-promoting effects (
JP-A-61-58584, JP-A No. 63-233783
JP-A No. 63-41421), anti-cataract effect (JP-A-63-41421).
同63−48215号公報、同64.−29313号公
報)、肝臓疾患予防治療作用(特開昭63−19271
7号公報)、創傷治癒作用(特開昭63−152309
号公報)、抗アレルギー作用(特開昭63−17493
号公報)、逆転写酵素阻害作用(特開昭63−1567
24号公報、特開平1−29313号公報)およびグリ
オキサラーゼエ阻害作用−制癌作用(特開昭63−21
5628号公報、特開平1−29313号公報)など多
くの生理活性が明らかにされている。Publication No. 63-48215, No. 64. -29313 Publication), liver disease preventive and therapeutic action (Japanese Unexamined Patent Publication No. 1987-19271)
7), wound healing effect (JP-A-63-152309)
(Japanese Patent Application Laid-Open No. 17493/1983), antiallergic effect
(Japanese Patent Application Laid-open No. 1567-1987), reverse transcriptase inhibitory effect
No. 24, JP-A No. 1-29313) and glyoxalase inhibitory effect-anticancer effect (JP-A No. 63-21)
5628, JP-A-1-29313), and many other physiological activities have been revealed.
しかしながら、PQQは、腎毒性を有することが近年間
らかにされ(渡辺ら、Hiroshima J 、Me
d 。However, in recent years it has been revealed that PQQ has nephrotoxicity (Watanabe et al., Hiroshima J, Me.
d.
Sei:、第38巻、1号2頁49〜51(1989年
乃、毒性および腎毒性が低く安全なPQQ誘導体の開発
が望まれている。Sei:, Vol. 38, No. 1, 2, pp. 49-51 (1989) The development of safe PQQ derivatives with low toxicity and nephrotoxicity is desired.
本発明者らは、種々のPQQ誘導体について、腎毒性お
よび急性毒性試験を行なったところ、オキサゾピロロキ
ノリン(OPQ)がこれらの毒性を大幅に軽減している
ことを見出した。The present inventors conducted nephrotoxicity and acute toxicity tests on various PQQ derivatives and found that oxazopyrroquinoline (OPQ) significantly reduced these toxicities.
しかして、OPQは、高純度のPQQとグリシンを反応
させて得られる方法(平成元年度日本化学会講演要旨集
2m B54)、PQQを含有する培養液にグリシ
ンを反応させる方法(特許出願平01−292459号
)が知られている。OPQ can be obtained by reacting high-purity PQQ with glycine (1989 Chemical Society of Japan Abstracts 2m B54), or by reacting glycine with a culture solution containing PQQ (patent application 2001). -292459) is known.
しかしながら、いずれの方法においても、反応の収率を
向上させるためには、PQQに対して過剰となる量のグ
リシンを添加する必要があり、より安価な原料による製
造法が期待されていた。However, in either method, in order to improve the reaction yield, it is necessary to add an excess amount of glycine to PQQ, and a production method using cheaper raw materials has been expected.
[問題を解決するための手段、作用]
本発明者らは、OPQのより安価な製造法について種々
検討した結果、PQQを含有する溶液中に、アンモニア
およびホルムアルデヒドを添加し酸素存在下で反応させ
ることにより、効率よくOPQに転換されることを見い
だし、本発明を完成した。[Means and effects for solving the problem] As a result of various studies on cheaper manufacturing methods for OPQ, the present inventors added ammonia and formaldehyde to a solution containing PQQ and reacted in the presence of oxygen. The present invention was completed based on the discovery that it can be efficiently converted to OPQ.
すなわち、本発明は、[ピロロキノリンキノンを含有す
る溶液に、アンモニアおよびホルムアルデヒドを添加し
、該溶液中のピロロキノリンキノンよりオキサゾピロロ
キノリンを生成するオキサゾピロロキノリンの製造法」
である。That is, the present invention provides a method for producing oxazopyrroquinoline, which involves adding ammonia and formaldehyde to a solution containing pyrroloquinoline quinone, and producing oxazopyrroquinoline from the pyrroloquinoline quinone in the solution.
It is.
本発明において使用されるPQQを含有する溶液として
は、
]、メタノールの資化性を有し、かつ、PQQを菌体外
に生産する能力を有する細菌をメタノールを炭素源とす
る培地中に培養して得られるPQQを含有する培養液
2、メタノールの資化性を有し、かつ、PQQを菌体外
に生産する能力を有する最近をメタノールを炭素源とす
る培地中に培養して得られるPQQを含有する培養液か
ら酸性処理、塩析処理などの方法により回収して得られ
た、PQQを含有する粉体を、水または緩衝液に溶解し
て得られる溶液3、高純度のPQQを、水または、緩衝
液に溶解して得られる溶液などがある。The PQQ-containing solution used in the present invention is as follows: ] Bacteria capable of assimilating methanol and capable of producing PQQ extracellularly are cultured in a medium using methanol as a carbon source. Culture solution 2 containing PQQ obtained by culturing in a medium using methanol as a carbon source Solution 3 obtained by dissolving PQQ-containing powder obtained by recovering PQQ-containing culture solution by acid treatment, salting-out treatment, etc. in water or buffer solution, high purity PQQ. , water or a solution obtained by dissolving it in a buffer solution.
このようにして得られたPQQを含有する溶液に、アン
モニアおよびホルムアルデヒドを添加し、該溶液中に含
まれるPQQと好気的条件下で反応させる。但し、該溶
液がPQQを含有する培養液で、十分量のアンモニアを
すでに含有している場合は、ホルムアルデヒドのみの添
加でも良い。Ammonia and formaldehyde are added to the PQQ-containing solution obtained in this manner and reacted with the PQQ contained in the solution under aerobic conditions. However, if the solution is a culture solution containing PQQ and already contains a sufficient amount of ammonia, only formaldehyde may be added.
このとき添加されるアンモニアとしては、硫酸アンモニ
ウム、塩化アンモニウムなどのアンモニウム塩類、アン
モニア水、アンモニアガスなどがあげられるが、実用上
は、アンモニア水、アンモニウム塩類が用いられる。Examples of the ammonia added at this time include ammonium salts such as ammonium sulfate and ammonium chloride, aqueous ammonia, and ammonia gas, but for practical purposes, aqueous ammonia and ammonium salts are used.
ホルムアルデヒドとしては、ホルムアルデヒド水溶液、
ホルムアルデヒドガスなどがあげられるが、実用上は、
ホルムアルデヒド水溶液(ホルマリン)が用いられる。As formaldehyde, formaldehyde aqueous solution,
Examples include formaldehyde gas, but in practical terms,
An aqueous formaldehyde solution (formalin) is used.
これらの化合物の添加量は、化学理論量以上であればよ
く、特に制限はないが、実用上は、アンモニアとしては
該溶液中に含有されているPQQに対して1〜1000
モル倍が好ましく、特に5〜100モル倍が好ましい。The amount of these compounds added is not particularly limited as long as it is a stoichiometric amount or more, but in practice, the amount of ammonia added is 1 to 1000 with respect to the PQQ contained in the solution.
It is preferably 5 to 100 times the amount by mole, particularly preferably 5 to 100 times by mole.
ホルムアルデヒドとしては、該溶液中に含有されている
PQQに対して1〜3000モル倍が好ましく、特に3
0〜1000モル倍が好ましい。Formaldehyde is preferably 1 to 3000 times the mole of PQQ contained in the solution, particularly 3
The amount is preferably 0 to 1000 times by mole.
反応液のpHは、3〜10の範囲が好ましく、pH4〜
8が特に好ましい。また、反応の進行とともに、T)H
が低下するので、該反応液のpHを保つため、アンモニ
ア、苛性カリ、苛性ソーダ等を添加して、該反応液のp
Hを調節する必要がある。The pH of the reaction solution is preferably in the range of 3 to 10, and preferably in the range of 4 to 10.
8 is particularly preferred. Also, as the reaction progresses, T)H
In order to maintain the pH of the reaction solution, ammonia, caustic potassium, caustic soda, etc. are added to lower the pH of the reaction solution.
It is necessary to adjust H.
温度は、15℃から80℃が好ましく、実用上特に25
〜50’Cが好ましい。The temperature is preferably from 15°C to 80°C, and for practical purposes, particularly 25°C.
~50'C is preferred.
また、該反応液中の容存酸素濃度には特に制限はないが
、反応を短時間で終了させるためには、0.5〜lpp
m以上が好ましい。そのために空気あるいは酸素または
その混合ガスなどを通気し、攪mlしたり、さらに、反
応槽の圧力を高めるなどの手段が使用される。このよう
な条件で反応させることによりPQQはOPQに変化す
る。In addition, there is no particular limit to the oxygen concentration in the reaction solution, but in order to complete the reaction in a short time, it is necessary to
m or more is preferable. For this purpose, measures such as aerating air, oxygen, or a mixed gas thereof, stirring the mixture, and increasing the pressure of the reaction tank are used. By reacting under such conditions, PQQ changes to OPQ.
このようにして得られた反応生成液は、PQQを含有す
る溶液としてPQQを含有する培養液などを用いた場合
、菌体、ホルムアルデヒドにより変性されたタンパク質
などの固形物が含まれているので、濾過もしくは遠心分
離などの通常の固液分離手段によって、固形分を除去し
、上澄液を得る。When a PQQ-containing culture solution is used as the PQQ-containing solution, the reaction product solution obtained in this way contains solid substances such as bacterial cells and proteins denatured by formaldehyde. Solids are removed by conventional solid-liquid separation means such as filtration or centrifugation to obtain a supernatant.
p、H3〜5などの低pHでOPQを生成させた場合、
生成したOPQが反応液中で沈澱物として存在している
場合もあるので、反応液のpHを中性以上にし、生成し
たOPQを一旦溶解した後、上澄液を得る必要がある。When OPQ is generated at low pH such as p, H3-5,
Since the produced OPQ may exist as a precipitate in the reaction solution, it is necessary to make the pH of the reaction solution above neutral and once dissolve the produced OPQ, and then obtain a supernatant.
得られた上澄液からOPQが分離・回収される。OPQ is separated and recovered from the obtained supernatant.
上澄液からのOPQの分離、採取方法は、それ自体公知
の方法によって行なうことが出来る。たとえば、イオン
交換クロマトグラフィー、濃縮物のゲル濾過、凍結乾燥
物の溶解抽出あるいはアフィニイティクロマトグラフィ
ーなどが利用できる。OPQ can be separated and collected from the supernatant by methods known per se. For example, ion exchange chromatography, gel filtration of concentrates, dissolution extraction of freeze-dried products, or affinity chromatography can be used.
OPQの同定には、元素分析、核磁気共鳴スペクトル、
赤外吸収スペクトルおよび質量分析などの手段が用いら
れる。Identification of OPQ requires elemental analysis, nuclear magnetic resonance spectroscopy,
Means such as infrared absorption spectroscopy and mass spectrometry are used.
また、OPQの定量は、高速液体クロマトグラフィーに
より行なうことが出来る。Furthermore, OPQ can be quantitatively determined by high performance liquid chromatography.
[実施例]
本発明を実施例によりさらに具体的に説明するが、本発
明はこれらの実施例に限定されるものではない。[Examples] The present invention will be explained in more detail with reference to Examples, but the present invention is not limited to these Examples.
実施例1
20(M容のビーカーにPQQ 100mgおよび蒸
留水80mQを入れ、溶液のpHを水酸化ナトリウムを
加えpH7,0とし、PQQを溶解した。このビーカー
に、37%ホルムアルデヒド水溶液10niおよび塩化
アンモニウム500mgを加え溶解し、溶液のpHを水
酸化ナトリウムを加えpH7,○とし、さらに蒸留水を
加え全量を100赫とした。Example 1 100 mg of PQQ and 80 mQ of distilled water were placed in a 20M beaker, and the pH of the solution was adjusted to pH 7.0 by adding sodium hydroxide to dissolve PQQ. In this beaker, 10 n of 37% formaldehyde aqueous solution and ammonium chloride 500 mg was added and dissolved, and the pH of the solution was adjusted to 7.0 by adding sodium hydroxide, and then distilled water was added to bring the total amount to 100 mg.
この溶液を攪拌子を用いて攪拌しながら、室温で24時
間反応させたところ、溶液中にOPQが30.9mg生
成した。When this solution was reacted at room temperature for 24 hours while being stirred using a stirrer, 30.9 mg of OPQ was produced in the solution.
実施例2
純水IQあたりに、(NH4) 2S○43.Og、K
H2PO41,4g、Na2HPO,,2,1g、Mg
SO4・7H,00,2g、 CaC1,・2H203
0mg、 FeC6H507・H2O30mg、 M
nCl24H205mg、ZnSO4・7H205mg
、 CuSO4・5H,00,5mg および メタノ
ール8mlを溶解し、p、 Hが7.1に調整された液
200mQを19容三角フラスコに入れ、120’Cで
20分間殺菌し、これを培地とした。Example 2 Per pure water IQ, (NH4) 2S○43. Og, K
H2PO41.4g, Na2HPO,,2.1g, Mg
SO4・7H,00,2g, CaC1,・2H203
0mg, FeC6H507・H2O30mg, M
nCl24H205mg, ZnSO4・7H205mg
, CuSO4.5H, 00.5 mg and 8 ml of methanol were dissolved and 200 mQ of the solution was adjusted to pH and H of 7.1, and then put into a 19-volume Erlenmeyer flask, sterilized at 120'C for 20 minutes, and used as a culture medium. .
これにハイホミクロビウム メチロボラム DSM
1869を接種し、30℃でロータリーシェーカーで回
転数220回/分の回転振盪培養を行った。この培養液
を種母液とした。Hyphomicrobium methyloborum DSM
1869 was inoculated, and cultured with a rotary shaker at 220 revolutions/min at 30°C. This culture solution was used as a seed mother solution.
純水IQあたりに、(NH4) 2S 04 1 、
Og、MgSO4・7H901,Og、 KH2PO
41,4gを添加した培地15Qを30Q容培養槽に入
れ、殺菌した。Per pure water IQ, (NH4) 2S 04 1,
Og, MgSO4・7H901, Og, KH2PO
Medium 15Q to which 41.4 g was added was placed in a 30Q culture tank and sterilized.
純水10戚あたりに、 FeSO4・7H7H2O75
,ZnSO4・7H20150mg、 Cacl、・
2H20150mg−NaC1150mg、MnSO4
・4〜5H2045mg、H2BO33mg、 Cu
SO4・5H201,5mg、COCl2・2H201
,5mg、KI 1.5mg、 (NH4)6Mo
702.・4H201,5mgを含むミネラル溶液を殺
菌した。FeSO4・7H7H2O75 per 10 relatives of pure water
, ZnSO4・7H20150mg, Cacl,・
2H20150mg-NaC1150mg, MnSO4
・4~5H2045mg, H2BO33mg, Cu
SO4・5H201,5mg, COCl2・2H201
,5mg, KI 1.5mg, (NH4)6Mo
702.・A mineral solution containing 1.5 mg of 4H20 was sterilized.
30Q容培養槽の温度が30’Cに低下した後、槽内の
培地に、このミネラル溶液10mΩを無菌的に加え、さ
らにアンモニア水を無菌的に添加して、培養液のpHを
6.8に調整した。After the temperature of the 30Q capacity culture tank decreased to 30'C, 10 mΩ of this mineral solution was added aseptically to the culture medium in the tank, and aqueous ammonia was added aseptically to adjust the pH of the culture solution to 6.8. Adjusted to.
この培養槽に、メタノールを150戚および前記の種母
液200薇を無菌的に加え、通気量10Q / m i
n、撹拌数30Orpmで温度30℃、培養pHを6
.8になるようにアンモニア水を添加しながら培養した
。細菌が増殖するに従って、培養液中のメタノール濃度
が低下したが、それを排気ガス中のメタノールをガスク
ロマトグラフィーで分析することにより検出し、培養液
中のメタノール濃度が0.1〜0.5重量%になるよう
にメタノールを供給した。To this culture tank, 150 ml of methanol and 200 ml of the above seed mother liquor were added aseptically, and the aeration rate was 10 Q/m i.
n, stirring number 30 rpm, temperature 30°C, culture pH 6
.. Culture was carried out while adding ammonia water so that the concentration of the cells was 8. As the bacteria proliferated, the methanol concentration in the culture solution decreased, but this was detected by analyzing methanol in the exhaust gas by gas chromatography, and it was found that the methanol concentration in the culture solution was 0.1 to 0.5. Methanol was supplied in an amount equal to % by weight.
このような方法により、3.OQ培養槽で10日間培養
し、PQQを361mg/2含有する培養液15Qを得
た。このPQQを含有する培養液に、37%ホルムアル
デヒド水溶液150mQを添加し、45髄の25%アン
モニア水を添加し、pH7゜0とし、攪拌数25Orp
m、通気量5 Q / m inで反応を行ったところ
、反応液のpHが低下したので、25%アンモニア水を
添加し、反応液中のpHを7.0にコントロールしなが
ら2時間反応を行ったところ、反応液中のoPQi度は
185mg/Ωとなった。なお、添加した25%アンモ
ニア水量は合計で71艷であった。By such a method, 3. The cells were cultured in an OQ culture tank for 10 days to obtain a culture solution 15Q containing 361 mg/2 of PQQ. To this PQQ-containing culture solution, 150 mQ of 37% formaldehyde aqueous solution was added, 45 marrow of 25% ammonia water was added, the pH was adjusted to 7°0, and the number of stirring was 25 Orp.
When the reaction was carried out at an aeration rate of 5 Q/min, the pH of the reaction solution decreased, so 25% ammonia water was added and the reaction was continued for 2 hours while controlling the pH in the reaction solution to 7.0. As a result, the oPQi degree in the reaction solution was 185 mg/Ω. The amount of 25% ammonia water added was 71 in total.
実施例3
実施例2と同様にして、ハイホミクロビウムメチロボラ
ム DSM 1869の培養を302容培養槽で10
日間行なった。その後、培養液を遠心分離し、得られた
培養上滑液に760gの塩化ナトリウムを添加し、塩酸
を用いて、pH3゜0とし、5℃で1晩静置し、遠心分
離によって沈澱物を集め、それを乾燥することにより、
粉体16.2gを得た。この粉体1gにはPQQを0゜
27g含有していた。Example 3 In the same manner as in Example 2, Hyphomicrobium methyloborum DSM 1869 was cultured for 10 times in a 302 volume culture tank.
I did it for days. Thereafter, the culture solution was centrifuged, 760 g of sodium chloride was added to the obtained cultured synovial fluid, the pH was adjusted to 3.0 with hydrochloric acid, and the mixture was left standing at 5°C overnight, and the precipitate was removed by centrifugation. By collecting and drying it,
16.2 g of powder was obtained. 1 g of this powder contained 0.27 g of PQQ.
この粉体12gを300mQの蒸留水に溶解し、NaO
Hを用いてpH7とし、100mQずつ3本の200m
Q、容三角フラスコに分注した。この溶液は、1070
mg/QのPQQを含有していた。。Dissolve 12 g of this powder in 300 mQ of distilled water, and
The pH was adjusted to 7 using H, and three 200 m
Q: Dispense into Erlenmeyer flask. This solution is 1070
It contained mg/Q of PQQ. .
各々の三角フラスコに、 (1)0.37%、(2)1
%、(3)2%のホルムアルデヒド濃度となるように3
7%ホルムアルデヒド水溶液を添加し、各々の三角フラ
スコに、塩化アンモニウム0.5gずつを添加し、Na
OHを用いてp、H7とし、25℃で24時間反応させ
た。In each Erlenmeyer flask, (1) 0.37%, (2) 1
%, (3) 3 to give a formaldehyde concentration of 2%.
Add 7% formaldehyde aqueous solution, add 0.5 g of ammonium chloride to each Erlenmeyer flask, and add Na
The p value was adjusted to H7 using OH, and the reaction was carried out at 25°C for 24 hours.
反応生成液中の○PQの含有量を第1表に示す。The content of ○PQ in the reaction product liquid is shown in Table 1.
第1表
[発明の効果]
本発明により、PQQからのオキサゾピロロキノリンの
製造を、より安価な方法で行うことが可能である。Table 1 [Effects of the Invention] According to the present invention, oxazopyrroquinoline can be produced from PQQ using a cheaper method.
Claims (1)
よびホルムアルデヒドを添加し、該溶液中のピロロキノ
リンキノンよりオキサゾピロロキノリンを生成するオキ
サゾピロロキノリンの製造法。A method for producing oxazopyrroquinoline, which comprises adding ammonia and formaldehyde to a solution containing pyrroloquinoline quinone, and producing oxazopyrroquinoline from the pyrroloquinoline quinone in the solution.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP33036090A JPH04202194A (en) | 1990-11-30 | 1990-11-30 | Production of oxazopyrroloquinoline |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP33036090A JPH04202194A (en) | 1990-11-30 | 1990-11-30 | Production of oxazopyrroloquinoline |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH04202194A true JPH04202194A (en) | 1992-07-22 |
Family
ID=18231742
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP33036090A Pending JPH04202194A (en) | 1990-11-30 | 1990-11-30 | Production of oxazopyrroloquinoline |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH04202194A (en) |
-
1990
- 1990-11-30 JP JP33036090A patent/JPH04202194A/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI103973B (en) | A method for purifying impure clavulanic acid | |
JP2751183B2 (en) | Method for producing pyrroloquinoline quinone | |
AU2019350699B2 (en) | Process of making calcium alpha-ketoglutarate | |
JPH04202194A (en) | Production of oxazopyrroloquinoline | |
JPH03294281A (en) | Method for producing oxazopyrroloquinolines | |
JP3791554B2 (en) | Method for producing imidazopyrroloquinoline | |
EP0251327B1 (en) | Process for production of anthracycline compound r2ox2 | |
JP3030896B2 (en) | WB968 substance group and production method thereof | |
JPH0570460A (en) | New pyrroloquinoline compound | |
JPH0565284A (en) | New imidazopyrroloquinoline compound | |
JPS62277373A (en) | Production of (-)-trans-2,3-epoxysuccinic acid by fermentation | |
JPS63233783A (en) | Method for culturing cells of bryophyte | |
CN116199591A (en) | Industrial preparation method of levocarnitine | |
JPS62215551A (en) | Novel physiologically active substance tpi and production thereof | |
CN100554433C (en) | A kind of novel synthesis of L-tryptophane | |
JPS61212587A (en) | G0069lambda substance | |
JPH04342590A (en) | Purification of ellagic acid | |
JPH01252295A (en) | Production of 2,3-dicyano-5,6-dicyanopurazine | |
JPS62190095A (en) | Production of coenzyme q11 | |
JPS6084295A (en) | Novel germanium compound and its production | |
JPH0538294A (en) | Production of labeled porphyrin compound | |
JPS59146596A (en) | Preparation of s-adenosyl-l-homocysteine | |
JPH06128258A (en) | Production of imidazopyrroloquinoline | |
JPH01172398A (en) | Production of anthracycline compound r20x2 | |
JPH048297A (en) | Production of d-aspartic acid |